// App-Quantinova.ai

277 : The Natural History of NPM1MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML)

Researchers

Presenter

  • Ing Soo Tiong

Principal Investigators

  • Richard Dillon

  • Adam Ivey

  • Chung Hoow Kok

  • James Anton Kuzich

  • Nisha Thiagarajah

  • Ashish Bajel

  • Nicola Potter

  • Matthew Smith

  • Claire Hemmaway

  • Abin Thomas

  • Amanda Gilkes

  • Nigel H. Russell

  • Andrew H. Wei

Medical Centers

  • Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • The Alfred Hospital and Monash University, Melbourne, Australia

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Medical and Molecular Genetics, Kings College, London, London, United Kingdom

  • Cancer Program, Precision Medicine Theme,South Australian Health and Medical Research Institute,Adelaide,Australia

  • Royal Melbourne Hospital, Melbourne, Australia

  • Cancer Genetics Laboratory, King's College, London, United Kingdom

  • Guy's Hospital, London, United Kingdom

  • Auckland City Hospital, Auckland, New Zealand

  • Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

  • Cardiff University, Cardiff, United Kingdom

  • Guy's Hospital, London, United Kingdom

  • Deakin University, Melbourne, Australia

Locations

  • Australia

  • United Kingdom

  • New Zealand

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Nucleophosmin 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved